Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stress Disorders, Post-Traumatic
Conditions
Stress Disorders, Post-Traumatic
Trial Timeline
Jan 26, 2017 → Nov 12, 2018
NCT ID
NCT03033069About Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching Placebo
Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching Placebo is a phase 2 stage product being developed by Lundbeck for Stress Disorders, Post-Traumatic. The current trial status is completed. This product is registered under clinical trial identifier NCT03033069. Target conditions include Stress Disorders, Post-Traumatic.
What happened to similar drugs?
8 of 20 similar drugs in Stress Disorders, Post-Traumatic were approved
Approved (8) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03033069 | Phase 2 | Completed |
Competing Products
20 competing products in Stress Disorders, Post-Traumatic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + placebo | Eli Lilly | Phase 2 | 35 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 19 |
| Thermal stress and performance without a pre-cooling protocol | Petros Pharmaceuticals | Pre-clinical | 16 |
| solifenacin | Astellas Pharma | Approved | 43 |
| Sivelestat | Eli Lilly | Phase 1/2 | 32 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 40 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 40 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 36 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| duloxetine + Placebo | Eli Lilly | Phase 2 | 35 |
| Exenatide + Insulin | Eli Lilly | Phase 2/3 | 38 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| duloxetine HCl | Eli Lilly | Approved | 43 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 47 |
| Duloxetine hydrochloride + placebo | Eli Lilly | Approved | 43 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 40 |
| duloxetine + placebo | Eli Lilly | Phase 3 | 40 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |